Clinical trials: Cyclooxygenase 2 Inhibitors
Low Back Pain
A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol
Non inferiority, multicentric, double blind study whose the primary objective is to compare the effectiveness of two products in pain reduction.
- Trial name
- NCT01421433
- Testing
- Tandrilax, Dolamin Flex
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- Farmoquimica S.A.
Osteoarthritis
A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain
The purpose of this study is to investigate which pain mechanisms that can be affected by etoricoxib compared to placebo (inactive medication)in subjects with painful knee osteoarthritis af 4 weeks of treatment.
- Trial name
- NCT01619150
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- C4Pain
Major Depression
Cimicoxib for the Treatment of Major Depression (SECIM)
This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression.
- Trial name
- NCT00510822
- Testing
- Cimicoxib
- Where
- 25 sites in Austria, Czechia and 1 more
- Volunteers
- 169 people
- Sponsor
- Affectis Pharmaceuticals AG
Osteoarthritis, Knee
Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
This study was designed to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of osteoarthritis of the knee.
- Trial name
- NCT00120900
- Testing
- GW406381
- Where
- 19 sites in Denmark, Netherlands and 4 more
- Volunteers
- 1,340 people
- Sponsor
- GlaxoSmithKline
Dental Pain, Surgery, Dental
Dental Pain (Following Third Molar Tooth Extraction) Study
The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
- Trial name
- NCT00114049
- Testing
- GW406381
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Acute Gouty Arthritis
Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
This study is designed to develop our understanding of the efficacy and safety of using lumiracoxib in the treatment of patients with acute gout.
- Trial name
- NCT00170781
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 234 people
- Sponsor
- Novartis
Localized Primary Osteoarthritis of Hip, Localized Primary Osteoarthritis of Knee
Phase III Study of CG100649 in Osteoarthritis Patients
6-week Efficacy Study The objective of this study is to prove the safety and non-inferiority of analgesic efficacy of CG100649 2 mg vs. celecoxib 200 mg, and analgesic superiority of CG100649 2 mg vs.
- Trial name
- NCT01765296
- Testing
- CG100649, Celecoxib
- Where
- 14 sites in South Korea
- Volunteers
- 362 people
- Sponsor
- CrystalGenomics, Inc.
Osteoarthritis
Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
This is a double-blind, randomized, multicenter, phase 2b, noninferiority comparison of two active dose levels of CG100649 vs. a standard anti-arthritic dose of celecoxib (Celebrex).
- Trial name
- NCT01341405
- Testing
- CG100649, Celecoxib
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- CrystalGenomics, Inc.
Musculoskeletal Pain
Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
This study is designed to develop our understanding of the risk-benefit of using lumiracoxib in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.
- Trial name
- NCT00170898
- Testing
- Lumiracoxib
- Where
- United Kingdom
- Volunteers
- 419 people
- Sponsor
- Novartis
Knee Osteoarthritis
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)
This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)
- Trial name
- NCT00367315
- Testing
- Lumiracoxib
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,684 people
- Sponsor
- Novartis
Arthritis, Rheumatoid
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
- Trial name
- NCT00113308
- Testing
- GW406381
- Where
- 341 sites in United States, Argentina and 31 more
- Volunteers
- 2,208 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis, Knee, Osteoarthritis, Hip
Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects
The primary objective of this study is to evaluate the safety and efficacy of 3 loading and maintenance dose levels of CG100649 administered for 21 days in the treatment of osteoarthritis pain.
- Trial name
- NCT00530452
- Testing
- CG100649, Silicified microcrystalline cellulose + talc
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- CrystalGenomics, Inc.
Pain
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic…
- Trial name
- NCT00333567
- Testing
- Lumiracoxib
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Novartis